EULAR points to consider in the match from PSO to PSA. 5 overarching principles and 10 points to consider. The presence of synovitis in PSO could be used as an outcome for prevention trials, Zabotti A et al, Abst#OP0062 #EULAR2023 @RheumNow https://t.co/tbnuhBCjTU

EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ

One new overarching principle for @eular_org PsA recommendations: “The choice of treatment should take account of safety considerations regarding individual MoA to optimize the benefit-risk profile” Wonder what triggered that #EULAR2023 #oralsurveillance @RheumNow https://t.co/19BfJQz4Za

Central sensitization of neuropathic pain in #PsA - patient reported outcomes. 114 pts. And 22 percent with fibromyalgia Pts with neuropathic pain didnt reach low disease activity or remission. @RheumNow #EULAR2023 highlights! https://t.co/Gxkcrruamp

#EULAR2023 recommendation update summary from the 2018 in #PsA whats new! - 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline) - safety now to to considered! - consider the full picture - extraarticular manifestations @rheumnow https://t.co/7GBILtCX4i

meds for PsA at #EULAR2023 recommendations bDMARD after csDMARD (no order proposed) @RheumNow https://t.co/bHMG4A8nmP